title: Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma.
abstract: In patients with hematologic malignancies, granulocyte colony-stimulating factor (G-CSF) following chemotherapy is widely used to mobilize peripheral blood progenitor cells (PBPCs), but there have been no trials comparing schedules of G-CSF following chemotherapy. We conducted a prospective randomized comparative observation of the mobilization with a single dose (10 microg kg once a day) or split dose (5 microg kg twice a day) of lenograstim following chemotherapy in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma (NHL) patients. Chemotherapy was cyclophosphamide 4 g/m2 for MM and ESHAP with or without Rituximab for NHL. The median number of harvested CD34+ cells was 19.4 x 10(6)/kg and 15.8 x 10(6)/kg in the single- and split-dose groups, respectively (p=0.47). Targeted collection of 5 x 10(6) CD34+ cells/kg was achieved in 18/20 patients in the single-dose group and in all 20 patients of the split-dose group (p=0.24), with the median number of sessions 1 and 2 in the single- and split-dose groups, respectively (p=0.13). We could not observe statistically significant differences between a single-dose and split-dose lenograstim following chemotherapy in enhancing the mobilization of PBPCs in MM or NHL patients.
authors.affiliation: Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors.forename: Shin
authors.initials: S
authors.lastname: Kim
authors.forename: Hyo-Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Jung Sun
authors.initials: JS
authors.lastname: Park
authors.forename: Jungsin
authors.initials: J
authors.lastname: Lee
authors.forename: Hyun-Sook
authors.initials: HS
authors.lastname: Chi
authors.forename: Chan Jeong
authors.initials: CJ
authors.lastname: Park
authors.forename: Jooryung
authors.initials: J
authors.lastname: Huh
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D000078224:Lenograstim; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim